KUS121, an ATP regulator, mitigates chorioretinal pathologies in animal models of age-related macular degeneration.

ABSTRACT: Age-related macular degeneration (AMD) is a leading cause of blindness among elderly people. The appearance of drusen is a clinical manifestation and a harbinger of both exudative and atrophic AMD. Recently, antibody-based medicines have been used to treat the exudative type. However, they do not restore good vision in patients. Moreover, no effective treatment is available for atrophic AMD. We have created small chemicals (Kyoto University Substances; KUSs) that act as ATP regulators inside cells. In the present study, we examined the in vivo efficacy of KUS121 in C-C chemokine receptor type 2-deficient mice, a mouse model of AMD. Systemic administration of KUS121 prevented or reduced drusen-like lesions and endoplasmic reticulum stress, and then substantially mitigated chorioretin

SUBMITTER: Muraoka Y 

PROVIDER: S-EPMC5986307 | biostudies-literature | 2018 May

REPOSITORIES: biostudies-literature